Pluslife recently hosted a delegation from the French Consulate General in Canton, CCI France Chine, and Haizhu District Investment Promotion Bureau to discuss advancements in molecular diagnostics, international cooperation, and strategies to enhance global health accessibility.

Focusing on Technology Application and Global Deployment

The delegation toured Pluslife’s corporate exhibition area to learn about the company’s global strategy and technological advancements in the molecular POCT sector. They also experienced the operation of Pluslife’s core product, the MiniDock device. The product’s advantages in speed, simplicity, accuracy, convenience, and efficiency left a deep impression on the visitors.

Exploring New Opportunities for Sino-French Cooperation

During the roundtable discussion, participants delved into how innovative technologies can enhance the accessibility of infectious disease diagnostics worldwide. Aligning with Pluslife’s current international business expansion strategy, the team introduced specific practices and development directions regarding global tuberculosis diagnostic accessibility projects and cooperation potential in Francophone countries.

• Deepening collaboration with public health departments, policy makers, and government procurement systems in Francophone countries within global public health;

• Promoting routine use of molecular diagnostics in primary care clinics and local medical service systems to improve frontline accessibility and coverage;

• Exploring the potential for molecular testing applications in home and retail settings to meet future diversified diagnostic scenarios.

The parties conducted extensive exchanges on the implementation of diagnostic products in low-resource settings and strengthening cooperation mechanisms with international NGOs and public health systems.

Building an Open and Innovative Ecosystem to Promote Global Health Accessibility

Pluslife sincerely thanks the French Consulate General in Canton, CCI France Chine, and the Haizhu District Investment Promotion Bureau for their ongoing attention and support to the company’s development. As an innovative molecular diagnostics enterprise rooted in China and serving the globe, Pluslife will continue to advance the accessibility and application of high-quality diagnostic products across broader scenarios, contributing to the strengthening of global public health systems and the enhancement of healthcare service capacity.